Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issues
the ONA take:
According to a new study published in the journal BJU International, researchers from Harvard Medical School and Brigham and Women's Hospital Cancer Center in Boston, Massachusetts, have found that men who were treated with androgen deprivation therapy for prostate cancer and have a past medical history of congestive heart failure or prior myocardial infarction have a three times increased risk of death from cardiac problems compared with those with no history of heart problems.
Previous studies have identified cardiac adverse effects from androgen deprivation therapy, so the team from Boston sought to investigate the association further. The researchers identified 5,077 patients with prostate cancer who received treatment between 1997 and 2006.
Patients were followed for a median of 4.8 years. Of the 30% that received androgen deprivation therapy, there was no association between androgen deprivation therapy and cardiac-related death among men with no history of cardiac issues. Men with a history of cardiac problems were found to have a 3.3-times increased risk of cardiac-related death compared with patients without cardiac issues.
The researchers explain that this study is limited by its retrospective design, and that future studies should follow patients for a longer period of time.
Men who were treated with ADT for prostate cancer have a three times increased risk of cardiac problems.
One of the main treatments for prostate cancer, androgen deprivation therapy (ADT) reduced male hormone levels in an effort to prevent them from stimulating cancer cells. However, previous studies have found some adverse effects to be associated with ADT, including increased risk of diabetes, coronary heart disease, heart attacks and sudden cardiac death.
To further investigate this link, a group of researchers from Brigham and Women's Cancer Center and Harvard Medical School - both in Boston, MA - analyzed data from 5,077 prostate cancer patients who were treated between 1997 and 2006. About 30% of the participants had been treated with ADT.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|